Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 2

A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease

NCT05104463 · View on ClinicalTrials.gov ↗

Study Summary

This is a Phase 2a, randomized, placebo-controlled, double-blind, crossover study to evaluate the effects CST-2032 administered with CST-107 on cognition in participants with Mild Cognitive Impairment (MCI) or mild dementia.

Interventions

  • DRUG CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107

Study Locations (15)

Florida

  • CuraSen Investigational Site — Boca Raton
  • CuraSen Investigational Site — Bradenton
  • CuraSen Investigational Site — Lady Lake
  • CuraSen Investigational Site — Miami
  • CuraSen Investigational Site — New Port Richey
  • CuraSen Investigational Site — Winter Park

Texas

  • CuraSen Investigational Site — Houston
  • CuraSen Investigational Site — Round Rock
  • CuraSen Investigational Site — Stafford

Arizona

  • CuraSen Investigational Site — Scottsdale

California

  • CuraSen Investigational Site — Lafayette

New York

  • CuraSen Investigational Site — New York

Ohio

  • CuraSen Investigational Site — Cincinnati

Utah

  • CuraSen Investigational Site — Salt Lake City

Other

  • CuraSen Investigational Site — Christchurch

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2022-04-11
Est. Completion 2024-02-01
Phase Phase 2

Sponsor

CuraSen Therapeutics

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05104463

The ClinicalTrials.gov registry entry for NCT05104463 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CuraSen Therapeutics, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 1 intervention — of which CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05104463 reports 15 study locations spanning 8 distinct geographic areas — top geographies include Florida, Texas, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05104463 about?

NCT05104463 is a clinical study titled "A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease". This is a Phase 2a, randomized, placebo-controlled, double-blind, crossover study to evaluate the effects CST-2032 administered with CST-107 on cognition in participants with Mild Cognitive Impairment (MCI) or mild dementia.

What is the current status of trial NCT05104463?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2022-04-11. Estimated completion is 2024-02-01.

What conditions does trial NCT05104463 study?

This clinical trial studies the following conditions: Mild Cognitive Impairment, Dementia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05104463?

The interventions under investigation include: CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05104463?

This trial is sponsored by CuraSen Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05104463 being conducted?

This trial has 15 study locations across Arizona, California, Florida, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial